Wen-Xuan Zhao

ORCID: 0009-0007-3407-8155
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Total Knee Arthroplasty Outcomes
  • Orthopaedic implants and arthroplasty
  • Orthopedic Infections and Treatments
  • Transplantation: Methods and Outcomes
  • Cancer Mechanisms and Therapy
  • Ferroptosis and cancer prognosis
  • Viral-associated cancers and disorders
  • Renal Transplantation Outcomes and Treatments
  • Immune cells in cancer

Jiangsu Province Hospital
2025

Nanjing University of Chinese Medicine
2025

Sichuan University
2024

State Key Laboratory of Biotherapy
2024

Atara Biotherapeutics (United States)
2022

To observe the inhibitory effect and potential mechanism of Yiqi Huayu Jiedu Decoction (YHJD) on liver metastasis colorectal cancer (CRC). We compared changes weight index before after YHJD treatment in CRC mouse models. HE staining was employed to pathological tissue sections. Flow cytometry used analyze number marker neutrophils treated with YHJD. Transcriptomics, proteomics, multiplex cytokine array analyses were conducted further verify role CXCL1. Differential gene analysis performed...

10.3389/fimmu.2025.1530053 article EN cc-by Frontiers in Immunology 2025-02-27

Objectives Residual varus after total knee arthroplasty (TKA) can affect functional outcomes, which may worsen in the presence of obesity. However, no studies were found to compare outcomes obese patients involving postoperative residual mild or neutral. The aim this study was complications and prosthesis survival, for knees with neutral TKA. Methods We retrospectively reviewed 188 consecutive (body mass index ≥30 kg/m 2 ) at our hospital who underwent TKA due osteoarthritis from January...

10.1111/os.14040 article EN cc-by Orthopaedic Surgery 2024-03-31

Background: Post-transplant lymphoproliferative disease (PTLD) is a rare and often aggressive i n the setting of immunosuppression following solid organ transplant (SOT). Epstein-Barr virus (EBV) infection B cells responsible for about 50% cases, either due to reactivation after transplantation or primary EBV infection. Although there no approved therapy patients (pts) with PTLD, guidelines include reduction (RIS) as part initial treatment may be sufficient pts early lesions. Rituximab,...

10.1097/01.hs9.0000847296.83232.25 article EN cc-by-nc-nd HemaSphere 2022-06-01
Coming Soon ...